Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab.

Andrew McGuireOlga KalininaEmma HolianCatherine CurranCarmel A MaloneRay McLaughlinAoife LoweryJames Andrew Lawrence BrownMichael J Kerin

Published in: Breast cancer research and treatment (2017)

An enhanced response to Trastuzumab was seen in Luminal B HER2 cancers. We highlight how Trastuzumab treatment changed the natural history of the HER2 receptor-positive breast cancer, demonstrating improved efficacy in changing the outcome of hormone receptor-positive patients.

Keyphrases

positive breast cancer
epidermal growth factor receptor
end stage renal disease
newly diagnosed
metastatic breast cancer
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
tyrosine kinase
patient reported outcomes